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A 29-year-old male developed cough in January of 2008, 2 months before seeking medical treatment. Patient’s 
past medical history was negative and unremarkable. 
Patient reported was a farmer, denying history of smoking, 
exposure to tuberculosis, or industrial dusts. There was no 
family history of cancer. Upon physical examination, there 
were no abnormal findings initially. Laboratory examina-
tions presented normal. Chest radiograph indicated right 
pulmonary hilar mass, thoracic computed tomography (CT) 
confirmed these findings, revealing a 6 × 6 centimeter nod-
ule in the right pulmonary hilar (Fig. 1A). Abdominal and 
head CT scans presented normal. A right middle and lower 
lobectomy with lymph node dissection of the hilum and 
mediastinum was performed. The tumor was 6 × 6 × 2 cm 
in diameter and the resected lymph node showed station 
11 of 12 lymph nodes metastasis. We made a diagnosis of 
stage II B according to the TNM Classiﬁcation of Malignant 
Tumors, 7th edition.
Histology examination which reviewed by two indepen-
dent pathologists indicated adenoid cystic carcinoma (ACC) 
of the lung (Fig. 2). Immunohistochemical stains demon-
strated P63 was positive (Fig. 3). One month post surgery, 
patient received chemotherapy regimen of GP (gemcitabine 
1000 mg/m2,D1,8; cisplatin 75 mg/m2 divided into D1-3; 21 
days every cycle, totally four cycles).
The patient developed liver metastasis in February, 
2012 (Fig. 1B). The biopsy of liver metastasis site was per-
formed and the histology confirmed as ACC of the lung 
(Fig. 4). Immunohistochemical stains demonstrated thyroid 
anscription factor 1 was negative. Patient received first-line 
chemotherapy with regimen of pemetrexed and cisplatin 
(pemetrexed 500 mg/m2, D1; cisplatin 75 mg/m2 divided into 
D1-3; 21 days every cycle, totally two cycles). Chemotherapy 
discontinued after 2 months because disease progression of 
new liver lesions.
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FIGURE 1. A, Computed tomography (CT; 2008/1) showing 
a nodule in the right pulmonary hilar. (B) CT (2012/2) show-
ing a new lesion emerged in liver. (C) CT (2013/11) showing 
liver lesion was stable.
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EGFR mutation status was determined using amplifi-
cation refractory mutation system method (Scorpion ARMS 
IVD2; Qiagen, Crawley, United Kingdom) and found to be 
positive in primary lung lesion and liver metastasis tissue 
(both were EGFR exon 19 E746-A 750 del).
In May 2012, patient was prescribed icotinib treatment 
(125 mg, three times per day). After 2 months of therapy, 
thoracic CT showed the lesion was stable. Patient continues 
icotinib treatment until now and no recurrence or progres-
sion happened with a progression-free survival more than 19 
months (Fig. 1C).
DISCUSSION
ACC of the lung is a malignant tumor arising in the tra-
cheobronchial glands distributed in the airway  submucosa, 
with represents 0.04–0.2% of all lung  cancers.1 In general, 
this lung tumor shows low grade malignancy with a 5 years 
survival rate approximately 90%.2
Surgical resection has been thought to be the most 
favorable procedure to control localized lesions in ACC of 
lung. There was some dispute for the treatment after com-
pletely resection. Radiation sensitivity is relatively high 
for this tumor and may be useful according to the previous 
reports.3,4 No standard chemotherapy regimen currently was 
found in ACC of lung. Third-generation drugs in non–small-
cell lung cancer was usually used in ACC of lung patients. 
However, the efficacy remains uncertain. The patient treated 
with gemcitabine and cisplatin and with 4 years of disease-
free survival time in our patients. However, the efficacy was 
limited in the first-line treatment with pemetrexed and cispla-
tin after liver metastasis.
The target therapy have increased the quality of life and 
prolonged the survival time in some solid tumors. Currently, 
EGFR-TKIs (including erlotinib, gefitinib, and icotinib) are 
selected mainly for advanced non–small-cell lung cancer 
patients. Patients with EGFR mutation showed a well efficacy 
with EGFR-TKIs in non–small-cell lung cancer. Dahse et al5 
reported a ACC of the lung patient with EGFR mutation in 
exon 19 and found that the frequency of EGFR mutation was 
rare (4%, 1 of 25). Because of the rarity of cases, there was 
no information in the efficacy of ACC of the lung with EGFR-
tyrosine kinase inhibitor treatment. To the best of our knowl-
edge, we present the first case of ACC of the lung patient 
with EGFR-tyrosine kinase inhibitor treatment and showed a 
well efficacy. There were no mixed histological subtypes in 
our patient such as adenocarcinoma which confirmed by two 
independent pathologists; however, different from most of 
FIGURE 2.  Histological findings showing primary adenoid 
cystic carcinoma of the lung (HE ×200).
FIGURE 3.  Immunohistochemistry of primary adenoid 
cystic carcinoma of the lung demonstrating the p63 positivity 
(×200).
FIGURE 4.  Histological findings showing adenoid cystic 
carcinoma of the liver tissue with biopsy (HE ×200).
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patients with EGFR mutation in adenocarcinoma, the patients 
achieved stable disease with icotinib treatment, the reason 
that might contribute to different biological characteristics 
between ACC and adenocarcinoma of lung.
In summary, we briefly described a case of ACC of 
the lung with liver metastasis after surgery. We achieved 
stable disease after icotinib treatment and maintenance 
progression-free survival more than 19 months, conclud-
ing with a relative positive efficacy and therapeutic role of 
EGFR-TKIs treatment. However, further investigations are 
required to support drug indications and final efficacy in 
ACC of the lung.
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